{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T01:37:07Z","timestamp":1788745027788,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.vaccine.2021.06.024","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T04:00:46Z","timestamp":1624507246000},"page":"4314-4319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-5507","authenticated-orcid":false,"given":"Sylvester","family":"Dassah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3622-2137","authenticated-orcid":false,"given":"Bright","family":"Adu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sodiomon B.","family":"Sirima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Mordm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulysse Ateba","family":"Ngoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Atuguba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fareed K.N.","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicta A.","family":"Mensah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7390-7330","authenticated-orcid":false,"given":"Mark","family":"Kaddumukasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Kremsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7109-9042","authenticated-orcid":false,"given":"Donnie","family":"Mategula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Flach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Theisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.06.024_b0005","unstructured":"World Health Organization. Fact sheet about Malaria [Internet]. 2019 [cited 2020 Jul 2]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/malaria."},{"issue":"1","key":"10.1016\/j.vaccine.2021.06.024_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2090-7214.1000282","article-title":"Pregnancy-associated Malaria, Challenges and Prospects in Sub-Saharan Africa","volume":"15","author":"Aguzie","year":"2018","journal-title":"Clinics Mother Child Health"},{"issue":"4","key":"10.1016\/j.vaccine.2021.06.024_b0015","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cell.2006.02.011","article-title":"Malaria: new vaccines for old?","volume":"124","author":"Waters","year":"2006","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.vaccine.2021.06.024_b0020","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1586\/14760584.7.5.597","article-title":"Malaria vaccines: a toy for travelers or a tool for eradication?","volume":"7","author":"Genton","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2021.06.024_b0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1586\/14760584.7.2.223","article-title":"Plasmodium falciparum malaria vaccines in development","volume":"7","author":"Vekemans","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"10.1016\/j.vaccine.2021.06.024_b0030","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1086\/656413","article-title":"Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia","volume":"51","author":"Richards","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2021.06.024_b0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/IAI.72.1.247-252.2004","article-title":"Association between Protection against Clinical Malaria and Antibodies to Merozoite Surface Antigens in an Area of Hyperendemicity in Myanmar: Complementarity between Responses to Merozoite Surface Protein 3 and the 220-Kilodalton Glutamate-Rich Protein","volume":"72","author":"Soe","year":"2004","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2021.06.024_b0040","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/infdis\/jit553","article-title":"Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria","volume":"209","author":"Tran","year":"2014","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2021.06.024_b0045","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1086\/315341","article-title":"Naturally Acquired Antibodies to the Glutamate-Rich Protein Are Associated with Protection against Plasmodium falciparum Malaria","volume":"181","author":"Dodoo","year":"2000","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2021.06.024_b0050","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1128\/IAI.69.9.5223-5229.2001","article-title":"Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity","volume":"69","author":"Theisen","year":"2001","journal-title":"Infect Immun"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2021.06.024_b0055","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.vaccine.2003.09.017","article-title":"A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies","volume":"22","author":"Theisen","year":"2004","journal-title":"Vaccine"},{"issue":"49","key":"10.1016\/j.vaccine.2021.06.024_b0060","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.1016\/j.vaccine.2009.09.011","article-title":"Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate","volume":"27","author":"Esen","year":"2009","journal-title":"Vaccine"},{"issue":"41","key":"10.1016\/j.vaccine.2021.06.024_b0065","doi-asserted-by":"crossref","first-page":"6698","DOI":"10.1016\/j.vaccine.2010.07.085","article-title":"Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambar\u00e9n\u00e9","volume":"28","author":"Mordm\u00fcller","year":"2010","journal-title":"Gabon Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2021.06.024_b0070","doi-asserted-by":"crossref","first-page":"e22525","DOI":"10.1371\/journal.pone.0022525","article-title":"A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children","volume":"6","author":"B\u00e9lard","year":"2011","journal-title":"PLoS ONE"},{"issue":"38","key":"10.1016\/j.vaccine.2021.06.024_b0075","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1016\/j.vaccine.2016.07.041","article-title":"A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children","volume":"34","author":"Sirima","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.06.024_b0080","unstructured":"World Health Organization, editor. Basic malaria microscopy. 2nd ed. Geneva: WHO; 2010. 2 p."},{"issue":"3","key":"10.1016\/j.vaccine.2021.06.024_b0085","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/sim.3783","article-title":"Estimation of intervention effects using first or multiple episodes in clinical trials: The Andersen-Gill model re-examined","volume":"29","author":"Cheung","year":"2010","journal-title":"Stat Med"},{"issue":"49","key":"10.1016\/j.vaccine.2021.06.024_b0090","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.1016\/j.vaccine.2009.09.011","article-title":"Safety and immunogenicity of GMZ2 \u2014 a MSP3\u2013GLURP fusion protein malaria vaccine candidate","volume":"27","author":"Esen","year":"2009","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.vaccine.2021.06.024_b0095","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","article-title":"Seven-Year Efficacy of RTS, S\/AS01 Malaria Vaccine among Young African Children","volume":"374","author":"Olotu","year":"2016","journal-title":"N Engl J Med"},{"issue":"10287","key":"10.1016\/j.vaccine.2021.06.024_b0100","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.06.024_b0105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev.immunol.21.120601.141126","article-title":"Toll-like receptors","volume":"21","author":"Takeda","year":"2003","journal-title":"Annu Rev Immunol"},{"issue":"17","key":"10.1016\/j.vaccine.2021.06.024_b0110","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1016\/j.vaccine.2011.02.022","article-title":"A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2\u2013a GLURP-MSP3 fusion protein malaria vaccine candidate","volume":"29","author":"Lousada-Dietrich","year":"2011","journal-title":"Vaccine"},{"issue":"1801","key":"10.1016\/j.vaccine.2021.06.024_b0115","first-page":"20142657","article-title":"Gradual acquisition of immunity to severe malaria with increasing exposure","volume":"282","author":"Griffin","year":"2015","journal-title":"Proc Biol Sci"},{"issue":"37","key":"10.1016\/j.vaccine.2021.06.024_b0120","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1016\/j.vaccine.2013.06.042","article-title":"A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria","volume":"31","author":"Murungi","year":"2013","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2021.06.024_b0125","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/14760584.2017.1355246","article-title":"The GMZ2 malaria vaccine: from concept to efficacy in humans","volume":"16","author":"Theisen","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.06.024_b0130","unstructured":"Garcia-Senosiain A, Kana IH, Singh SK, Chourasia BK, Das MK, Dodoo D, et al. Peripheral merozoite surface proteins are targets of naturally acquired immunity against malaria both in India and in Ghana. Infection and Immunity [Internet]. 2020 Jan 21 [cited 2020 Mar 10]; Available from: https:\/\/iai.asm.org\/content\/early\/2020\/01\/15\/IAI.00778-19."},{"issue":"2","key":"10.1016\/j.vaccine.2021.06.024_b0135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/infdis\/jiz088","article-title":"Breadth of Functional Antibodies Is Associated With Plasmodium falciparum Merozoite Phagocytosis and Protection Against Febrile Malaria","volume":"220","author":"Kana","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.06.024_b0140","doi-asserted-by":"crossref","unstructured":"Tijani MK, Reddy SB, Langer C, Beeson JG, Wahlgren M, Nwuba RI, et al. Factors influencing the induction of high affinity antibodies to Plasmodium falciparum merozoite antigens and how affinity changes over time. Scientific Reports [Internet]. 2018 [cited 2019 May 28];8. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5998021\/.","DOI":"10.1038\/s41598-018-27361-w"},{"issue":"2","key":"10.1016\/j.vaccine.2021.06.024_b0145","doi-asserted-by":"crossref","first-page":"e32242","DOI":"10.1371\/journal.pone.0032242","article-title":"High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria","volume":"7","author":"Reddy","year":"2012","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.vaccine.2021.06.024_b0150","doi-asserted-by":"crossref","first-page":"e64073","DOI":"10.1371\/journal.pone.0064073","article-title":"Phase 1b Randomized Trial and Follow-Up Study in Uganda of the Blood-Stage Malaria Vaccine Candidate BK-SE36","volume":"8","author":"Palacpac","year":"2013","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.vaccine.2021.06.024_b0155","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1128\/iai.60.4.1473-1481.1992","article-title":"Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity","volume":"60","author":"Bouharoun-Tayoun","year":"1992","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2021.06.024_b0160","first-page":"135","article-title":"Characterization of the humoral immune response in Plasmodium falciparum malaria. II. IgG subclass levels of anti-P. falciparum antibodies in different sera","volume":"54","author":"Wahlgren","year":"1983","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2021.06.024_b0165","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1128\/iai.59.10.3547-3554.1991","article-title":"Antimalarial antibodies of the immunoglobulin G2a isotype modulate parasitemias in mice infected with Plasmodium yoelii","volume":"59","author":"White","year":"1991","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2021.06.024_b0170","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/eji.1830170504","article-title":"Isotypic pattern of the polyclonal B cell response during primary infection by Plasmodium chabaudi and in immune-protected mice","volume":"17","author":"Falanga","year":"1987","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2021.06.024_b0175","unstructured":"World Health Organization (WHO). WHO | Malaria vaccine technology roadmap [Internet]. WHO. 2018 [cited 2018 Aug 13]. Available from: http:\/\/www.who.int\/immunization\/topics\/malaria\/vaccine_roadmap\/en\/."},{"issue":"11","key":"10.1016\/j.vaccine.2021.06.024_b0180","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1008115","article-title":"A Field Trial to Assess a Blood-Stage Malaria Vaccine","volume":"365","author":"Thera","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2021.06.024_b0185","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1086\/339342","article-title":"A Recombinant Blood-Stage Malaria Vaccine Reduces Plasmodium falciparum Density and Exerts Selective Pressure on Parasite Populations in a Phase 1\u20132b Trial in Papua New Guinea","volume":"185","author":"Genton","year":"2002","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2021.06.024_b0190","doi-asserted-by":"crossref","first-page":"e5254","DOI":"10.1371\/journal.pone.0005254","article-title":"Phase 1\/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A","volume":"4","author":"Spring","year":"2009","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.vaccine.2021.06.024_b0195","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/mt.2012.223","article-title":"ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans","volume":"20","author":"Sheehy","year":"2012","journal-title":"Mol Ther"},{"issue":"11","key":"10.1016\/j.vaccine.2021.06.024_b0200","doi-asserted-by":"crossref","first-page":"e79323","DOI":"10.1371\/journal.pone.0079323","article-title":"Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial","volume":"8","author":"Laurens","year":"2013","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.vaccine.2021.06.024_b0205","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1128\/IAI.73.6.3677-3685.2005","article-title":"Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria","volume":"73","author":"Malkin","year":"2005","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2021.06.024_b0210","doi-asserted-by":"crossref","first-page":"e1045","DOI":"10.1371\/journal.pone.0001045","article-title":"Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians","volume":"2","author":"Dicko","year":"2007","journal-title":"PLoS ONE"},{"issue":"192","key":"10.1016\/j.vaccine.2021.06.024_b0215","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/192733a0","article-title":"Gamma-globulin and acquired immunity to human malaria","volume":"25","author":"Cohen","year":"1961","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2021.06.024_b0220","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4269\/ajtmh.1991.45.297","article-title":"Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria","volume":"45","author":"Sabchareon","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2021.06.024_b0225","doi-asserted-by":"crossref","unstructured":"Didierlaurent AM, Berger A, Heineman TC, Henderickx V, Tavares Da Silva F, Vekemans J, et al. Chapter 14 - The Development of the Adjuvant System AS01: A Combination of Two Immunostimulants MPL and QS-21 in Liposomes. In: Schijns VEJC, O\u2019Hagan DT, editors. Immunopotentiators in Modern Vaccines (Second Edition) [Internet]. Academic Press; 2017 [cited 2018 Oct 8]. p. 265\u201385. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780128040195000141.","DOI":"10.1016\/B978-0-12-804019-5.00014-1"},{"issue":"1","key":"10.1016\/j.vaccine.2021.06.024_b0230","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/meth.1999.0834","article-title":"Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines","volume":"19","author":"Baldridge","year":"1999","journal-title":"Methods"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2100760X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2100760X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:57:28Z","timestamp":1759402648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2100760X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":46,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0264410X2100760X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.06.024","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}